Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

NCT05810792 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Surgery
Metastasis
Immunosuppression

Interventions

DRUG: Histamine Dihydrochloride (HDC)
DRUG: Interleukin-2 (IL-2)

Sponsor

Sahlgrenska University Hospital